drugset / Trial / NCT00311467
Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
Multi-center, prospective randomised phase III study evaluating capecitabine in combination with standard-immunotherapy versus standard-immunotherapy alone as first-line therapy in patients with metastatic renal cell carcinoma.
Timeline
- Start
- 2004-03
- Primary completion
- 2007-05
- Completion
- 2007-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Comparator | aldesleukin | Protein / enzyme biologic | 4.5e+06 iu | Subcutaneous |
| Comparator | interferon alfa-2b | Protein / enzyme biologic | 6e+06 iu | Subcutaneous |